128 related articles for article (PubMed ID: 37774895)
1. Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism.
Ma X; Yu X; Li R; Cui J; Yu H; Ren L; Jiang J; Zhang W; Wang L
J Ethnopharmacol; 2024 Jan; 319(Pt 2):117238. PubMed ID: 37774895
[TBL] [Abstract][Full Text] [Related]
2. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
3. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Xu X; Zhu XP; Bai JY; Xia P; Li Y; Lu Y; Li XY; Gao X
FASEB J; 2019 Jun; 33(6):7289-7300. PubMed ID: 30848932
[TBL] [Abstract][Full Text] [Related]
4. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
5. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
[TBL] [Abstract][Full Text] [Related]
6. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
Cui CX; Deng JN; Yan L; Liu YY; Fan JY; Mu HN; Sun HY; Wang YH; Han JY
J Ethnopharmacol; 2017 Aug; 208():24-35. PubMed ID: 28648927
[TBL] [Abstract][Full Text] [Related]
7. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways.
Wang Y; Tai YL; Zhao D; Zhang Y; Yan J; Kakiyama G; Wang X; Gurley EC; Liu J; Liu J; Liu J; Lai G; Hylemon PB; Pandak WM; Chen W; Zhou H
Cells; 2021 Jan; 10(2):. PubMed ID: 33494295
[TBL] [Abstract][Full Text] [Related]
8. Hydrochloride Berberine ameliorates alcohol-induced liver injury by regulating inflammation and lipid metabolism.
Ke X; Zhang R; Li P; Zuo L; Wang M; Yang J; Wang J
Biochem Biophys Res Commun; 2022 Jun; 610():49-55. PubMed ID: 35436630
[TBL] [Abstract][Full Text] [Related]
9. Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice.
Xue M; Zhang L; Yang MX; Zhang W; Li XM; Ou ZM; Li ZP; Liu SH; Li XJ; Yang SY
Int J Nanomedicine; 2015; 10():5049-57. PubMed ID: 26346310
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
Yan HM; Xia MF; Wang Y; Chang XX; Yao XZ; Rao SX; Zeng MS; Tu YF; Feng R; Jia WP; Liu J; Deng W; Jiang JD; Gao X
PLoS One; 2015; 10(8):e0134172. PubMed ID: 26252777
[TBL] [Abstract][Full Text] [Related]
11. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver.
Yu M; Alimujiang M; Hu L; Liu F; Bao Y; Yin J
Int J Biol Sci; 2021; 17(7):1693-1707. PubMed ID: 33994854
[TBL] [Abstract][Full Text] [Related]
12. Berberine in Non-Alcoholic Fatty Liver Disease-A Review.
Koperska A; Wesołek A; Moszak M; Szulińska M
Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079717
[TBL] [Abstract][Full Text] [Related]
13. Excess fructose and fatty acids trigger a model of non‑alcoholic fatty liver disease progression in vitro: Protective effect of the flavonoid silybin.
Grasselli E; Baldini F; Vecchione G; Oliveira PJ; Sardão VA; Voci A; Portincasa P; Vergani L
Int J Mol Med; 2019 Aug; 44(2):705-712. PubMed ID: 31173180
[TBL] [Abstract][Full Text] [Related]
14. Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine.
Xiong W; Sang W; Linghu KG; Zhong ZF; Cheang WS; Li J; Hu YJ; Yu H; Wang YT
Int J Nanomedicine; 2018; 13():3781-3793. PubMed ID: 29988733
[TBL] [Abstract][Full Text] [Related]
15. Tiaogan Jiejiu Tongluo Formula attenuated alcohol-induced chronic liver injury by regulating lipid metabolism in rats.
Fang C; Zhang J; Han J; Lei Y; Cao Z; Pan J; Pan Z; Zhang Z; Qu N; Luo H; Ma Y; Han D
J Ethnopharmacol; 2023 Dec; 317():116838. PubMed ID: 37355081
[TBL] [Abstract][Full Text] [Related]
16. Berberine Ameliorates Abnormal Lipid Metabolism via the Adenosine Monophosphate-Activated Protein Kinase/Sirtuin 1 Pathway in Alcohol-Related Liver Disease.
Zhu L; Xu JJ; Li HD; Li JJ; Cheng M; Niu XN; Jia PC; Liu JY; Huang C; Lv XW; Li J
Lab Invest; 2023 Apr; 103(4):100041. PubMed ID: 36870291
[TBL] [Abstract][Full Text] [Related]
17. The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease.
Zhu X; Bian H; Gao X
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754444
[TBL] [Abstract][Full Text] [Related]
18. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
19. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.
Chang X; Wang Z; Zhang J; Yan H; Bian H; Xia M; Lin H; Jiang J; Gao X
J Transl Med; 2016 Sep; 14():266. PubMed ID: 27629750
[TBL] [Abstract][Full Text] [Related]
20. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles.
Yuan X; Wang J; Tang X; Li Y; Xia P; Gao X
J Transl Med; 2015 Jan; 13():24. PubMed ID: 25623289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
